macular degeneration

View All

Pharma News and Updates for RegeneRx, Aldeyra, Oncolyze, Soligenix, Aviceda
RegeneRx’s Phase 3 Neurotrophic Keratitis Clinical Trial of RGN-259; Aldeyra’s Phase 3 INVIGORATE-2 Clinical Trial Update; FDA Orphan Drug Designation to Oncolyze’s OM-301 for Multiple Myeloma; Soligenix Provides Regulatory Update on HyBryte; FDA Fast Track Designation to SAB Biotherapeutics’s SAB-176 Influenza Immunotherapy; Aviceda IND Application for AVD-104

RegeneRx Biopharmaceuticals Enrolled First Patient in the Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259 in the US On April 12, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company") announced that the first patient of Phase 3 clinical trial (SEER-2) of RGN-259, a novel treat...

Find More

cornea
Japan has got new ways to treat corneas

The Cornea- the outermost layer in the human eye, plays an important role in regulating the amount of light entering into the eye. It also protects the eye from germs, dust, and other harmful matter. Although this important part of the human body has a countless number of ways to get damaged. Corneal Abrasions, Dry...

Find More

Wet AMD: A chronic eye condition with promising therapies

Wet AMD is a chronic eye disease that causes blurred vision or a blind spot in a person’s visual field. It is characterized by abnormal blood vessels that leak blood and fluids into the macula, a region of the eye that is responsible for sharp, central vision. Age-related macular degeneration (AMD) is a common eye c...

Find More